These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 30579113)

  • 1. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
    Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
    Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
    Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
    Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
    J Neurosurg; 2019 Mar; 130(3):780-788. PubMed ID: 29726772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
    Amatu A; Barault L; Moutinho C; Cassingena A; Bencardino K; Ghezzi S; Palmeri L; Bonazzina E; Tosi F; Ricotta R; Cipani T; Crivori P; Gatto R; Chirico G; Marrapese G; Truini M; Bardelli A; Esteller M; Di Nicolantonio F; Sartore-Bianchi A; Siena S
    Ann Oncol; 2016 Jun; 27(6):1062-1067. PubMed ID: 26916096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
    Morano F; Corallo S; Niger M; Barault L; Milione M; Berenato R; Moretto R; Randon G; Antista M; Belfiore A; Raimondi A; Nichetti F; Martinetti A; Battaglia L; Perrone F; Pruneri G; Falcone A; Di Bartolomeo M; de Braud F; Di Nicolantonio F; Cremolini C; Pietrantonio F
    Ann Oncol; 2018 Aug; 29(8):1800-1806. PubMed ID: 29860358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Wick A; Kessler T; Platten M; Meisner C; Bamberg M; Herrlinger U; Felsberg J; Weyerbrock A; Papsdorf K; Steinbach JP; Sabel M; Vesper J; Debus J; Meixensberger J; Ketter R; Hertler C; Mayer-Steinacker R; Weisang S; Bölting H; Reuss D; Reifenberger G; Sahm F; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2020 Aug; 22(8):1162-1172. PubMed ID: 32064499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
    Richard S; Tachon G; Milin S; Wager M; Karayan-Tapon L
    Cancer Med; 2020 Sep; 9(17):6344-6353. PubMed ID: 32666673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy in osteosarcoma.
    Uchihara Y; Umeda K; Yamada Y; Ito H; Tasaka K; Isobe K; Akazawa R; Kawabata N; Saida S; Kato I; Hiramatsu H; Noguchi T; Sakamoto A; Arakawa Y; Arakawa A; Yamamoto N; Hosoya Y; Uemura S; Watanabe KI; Sano H; Taga T; Takita J
    Cancer Sci; 2024 Oct; 115(10):3394-3402. PubMed ID: 39080996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of
    Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
    Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
    Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
    J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
    Brawanski KR; Sprung S; Freyschlag CF; Hoeftberger R; Ströbel T; Haybaeck J; Thomé C; Manzl C; Birkl-Toeglhofer AM
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
    Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
    Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
    Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
    J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Sartore-Bianchi A; Pietrantonio F; Amatu A; Milione M; Cassingena A; Ghezzi S; Caporale M; Berenato R; Falcomatà C; Pellegrinelli A; Bardelli A; Nichelatti M; Tosi F; De Braud F; Di Nicolantonio F; Barault L; Siena S
    Eur J Cancer; 2017 Jan; 71():43-50. PubMed ID: 27997874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.